Gift an article

Covid-19 vaccines vs antivirals: Compared to jabs, why are treatments lagging behind in development?

accreditation
Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
loading...
Loading, please wait...
0:00
play article
Subscribers can listen to this article
Merck's molnupiravir showed great promise for reducing the risk of Covid-19-related hospitalisation and death in a clinical trial.
Merck's molnupiravir showed great promise for reducing the risk of Covid-19-related hospitalisation and death in a clinical trial.
Plyushkin

Merck's molnupiravir showed great promise for reducing the risk of Covid-19-related hospitalisation and death in a clinical trial. The pill is pending authorisation by the US Food and Drug Administration (FDA) and, if approved, people at high risk of severe Covid-19 would need to take four capsules twice a day for five days at the onset of infection.

To date, the FDA has only fully approved one treatment for Covid-19 – the antiviral remdesivir, which is administered intravenously (via injection) and has been found to shorten recovery time in hospitalised patients, although its effectiveness is debated.

According to the New York Times' treatments and vaccines trackers, 25 other medical treatments for Covid-19 are tentative, compared to 105 vaccines currently being tested in clinical trials.

Read this for free
Get 14 days free to read all our investigative and in-depth journalism. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed.
Try FREE for 14 days
Already a subscriber? Sign in
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE